US6225310B1
(en)
|
1996-01-17 |
2001-05-01 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
AUPO227896A0
(en)
|
1996-09-13 |
1996-10-03 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel compounds and their preparation
|
ES2136013B1
(es)
*
|
1997-04-15 |
2000-07-01 |
Consejo Superior Investigacion |
Derivados de tieno y pirazolo (1,2,4) tiadiazina-1,1-dioxido farmacologicamente activos.
|
JP2001510195A
(ja)
*
|
1997-07-16 |
2001-07-31 |
ノボ ノルディスク アクティーゼルスカブ |
縮合化1,2,4−チアジアジン誘導体、その調製及び使用
|
WO1999032494A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
EP1338600A1
(en)
*
|
1998-12-18 |
2003-08-27 |
Novo Nordisk A/S |
Fused 1,2,4-Thiadiazine derivatives, their preparation and use
|
US6329367B1
(en)
|
1998-12-18 |
2001-12-11 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
JP2002539202A
(ja)
*
|
1999-03-12 |
2002-11-19 |
ノボ ノルディスク アクティーゼルスカブ |
融合1,4−チアジン−2−カルボニトリル誘導体、その製造および使用
|
US6232310B1
(en)
|
1999-03-12 |
2001-05-15 |
Novo Nordisk A/S |
Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
|
US6197765B1
(en)
|
1999-06-08 |
2001-03-06 |
Pnina Vardi |
Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
|
JP2003525211A
(ja)
*
|
1999-06-30 |
2003-08-26 |
ノボ ノルディスク アクティーゼルスカブ |
新規方法
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
AU2001265839A1
(en)
*
|
2000-06-26 |
2002-01-08 |
Novo-Nordisk A/S |
Use of potassium channel agonists for the treatment of cancer
|
WO2002000665A1
(en)
*
|
2000-06-26 |
2002-01-03 |
Novo Nordisk A/S |
Use of potassium channel openers for the treatment of insulitis
|
RS50864B
(sr)
|
2000-12-21 |
2010-08-31 |
Sanofi-Aventis Deutschland Gmbh. |
Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
|
WO2002050085A1
(en)
*
|
2000-12-21 |
2002-06-27 |
Novo Nordisk A/S |
A new process for preparing fused 1,2,4-thiadiazine derivatives
|
IL156548A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
DE10110747A1
(de)
*
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
|
DE10142660A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
JP2005501861A
(ja)
|
2001-08-22 |
2005-01-20 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
1,4−ベンゾチエピン1,1−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
|
DE10142665B4
(de)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-one und ihre Derivate
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
DE10142668A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142661B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
|
DE10142722A1
(de)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Gmbh |
C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10142662B4
(de)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
|
DE10142666A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142659A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142667B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
KR100915108B1
(ko)
|
2001-08-31 |
2009-09-03 |
사노피-아벤티스 도이칠란트 게엠베하 |
Ppar-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
|
EP1444219A1
(en)
|
2001-10-12 |
2004-08-11 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
US20030109519A1
(en)
*
|
2001-11-30 |
2003-06-12 |
Jeppe Sturis |
Use of selective potassium channel openers
|
AU2002342600A1
(en)
*
|
2001-11-30 |
2003-06-10 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
WO2003045955A1
(en)
*
|
2001-11-30 |
2003-06-05 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
WO2003055482A1
(en)
|
2001-12-21 |
2003-07-10 |
Novo Nordisk A/S |
Amide derivatives as gk activators
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
WO2003105896A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a beta cell resting compound
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
EP1531815B1
(en)
|
2002-06-27 |
2014-09-24 |
Novo Nordisk A/S |
Glucokinase activators
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
PL373329A1
(en)
|
2002-07-12 |
2005-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
WO2004089470A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
New amide derivatives and pharmaceutical use thereof
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
WO2004071458A2
(en)
*
|
2003-02-13 |
2004-08-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
BRPI0414890A
(pt)
|
2003-09-30 |
2006-12-12 |
Novo Nordisk As |
composto, métodos de retardar a progressão de igt para diabete tipo 2, e de diabete tipo 2 para diabete que requer insulina, de tratar a obesidade ou prevenir o excesso de peso, de regular o apetite, de induzir saciedade, de impedir o ganho de peso, de aumentar o gasto de energia, e de tratar uma doença ou estado, composição farmacêutica, e, uso de um composto
|
JP4865565B2
(ja)
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストを用いた食物選択の制御
|
PT1723128E
(pt)
|
2004-01-06 |
2013-02-27 |
Novo Nordisk As |
Heteroaril-ureias e o seu uso como activadores da glicoquinase
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
GT200500063A
(es)
|
2004-04-01 |
2005-10-14 |
|
Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
US20050261292A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
|
JP2008501765A
(ja)
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1アゴニストを用いた薬剤誘発性肥満の中和
|
DE102004042607A1
(de)
*
|
2004-09-03 |
2006-03-09 |
Bayer Healthcare Ag |
Substituierte Phenylaminothiazole und ihre Verwendung
|
WO2006041922A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Dara Biosciences, Inc. |
Agents and methods for administration to the central nervous system
|
WO2006053906A1
(en)
|
2004-11-22 |
2006-05-26 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
EP1824835A1
(en)
|
2004-12-03 |
2007-08-29 |
Novo Nordisk A/S |
Heteroaromatic glucokinase activators
|
JP4933455B2
(ja)
|
2005-02-02 |
2012-05-16 |
ノヴォ ノルディスク アー/エス |
新規のインスリン誘導体
|
ES2490243T3
(es)
|
2005-02-02 |
2014-09-03 |
Novo Nordisk A/S |
Derivados de insulina
|
US20090012067A1
(en)
*
|
2005-02-14 |
2009-01-08 |
Luciano Rossetti |
Modulation of Hypothalamic Atp-Sensitive Potassium Channels
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
AU2006265172B2
(en)
|
2005-06-30 |
2011-09-15 |
Vtv Therapeutics Llc |
Phenoxy acetic acids as PPAR delta activators
|
US8501739B2
(en)
|
2005-07-04 |
2013-08-06 |
High Point Pharmaceuticals, Llc |
Medicaments
|
US7884210B2
(en)
|
2005-07-14 |
2011-02-08 |
Novo Nordisk A/S |
Ureido-thiazole glucokinase activators
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
PT1951658E
(pt)
|
2005-11-17 |
2012-11-12 |
Lilly Co Eli |
Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
|
EA201101085A1
(ru)
|
2005-12-22 |
2012-05-30 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Феноксиуксусные кислоты в качестве активаторов ppar дельта
|
CN101443314B
(zh)
|
2006-03-13 |
2014-04-09 |
杏林制药株式会社 |
作为gsk-3抑制剂的氨基喹诺酮类
|
AU2007229492B2
(en)
|
2006-03-28 |
2011-11-03 |
High Point Pharmaceuticals, Llc |
Benzothiazoles having histamine H3 receptor activity
|
KR20090040259A
(ko)
|
2006-05-29 |
2009-04-23 |
하이 포인트 파마슈티칼스, 엘엘씨 |
3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 h3 수용체 안타고니스트로서의 용도
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
RU2009108280A
(ru)
|
2006-08-08 |
2010-09-20 |
Санофи-Авентис (Fr) |
Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
|
DE102006042143A1
(de)
*
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
US7776178B2
(en)
*
|
2006-10-25 |
2010-08-17 |
Applied Materials, Inc. |
Suspension for showerhead in process chamber
|
ES2377322T3
(es)
|
2006-11-15 |
2012-03-26 |
High Point Pharmaceuticals, Llc |
Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes
|
DE102006056739A1
(de)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
|
DE102006056740A1
(de)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
|
AU2008204530B2
(en)
|
2007-01-11 |
2013-08-01 |
Vtv Therapeutics Llc |
Urea glucokinase activators
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
DE102007035367A1
(de)
|
2007-07-27 |
2009-01-29 |
Bayer Healthcare Ag |
Substituierte Aryloxazole und ihre Verwendung
|
DE102007036076A1
(de)
|
2007-08-01 |
2009-02-05 |
Bayer Healthcare Aktiengesellschaft |
Dipeptoid-Produgs und ihre Verwendung
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007042754A1
(de)
*
|
2007-09-07 |
2009-03-12 |
Bayer Healthcare Ag |
Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
|
AU2008299903B2
(en)
|
2007-09-11 |
2013-08-29 |
Kyorin Pharmaceutical Co., Ltd |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
KR101597841B1
(ko)
|
2007-09-12 |
2016-02-26 |
교린 세이야꾸 가부시키 가이샤 |
Gsk-3 억제제로서의 스피로시클릭 아미노퀴놀론
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
DE102007061757A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
|
DE102007061756A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
|
DE102007061764A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Anellierte Cyanopyridine und ihre Verwendung
|
DE102007061763A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte azabicyclische Verbindungen und ihre Verwendung
|
DE102008008838A1
(de)
|
2008-02-13 |
2009-08-20 |
Bayer Healthcare Ag |
Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
|
DE102008013587A1
(de)
|
2008-03-11 |
2009-09-17 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(zh)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
|
US20090257979A1
(en)
*
|
2008-04-15 |
2009-10-15 |
Intermune, Inc. |
Novel Inhibitors of Hepatitis C Virus Replication
|
EP2297104B1
(de)
*
|
2008-05-29 |
2013-08-07 |
Bayer Intellectual Property GmbH |
2-alkoxy-substituierte dicyanopyridine und ihre verwendung
|
TW201014822A
(en)
|
2008-07-09 |
2010-04-16 |
Sanofi Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
US8927549B2
(en)
|
2008-11-21 |
2015-01-06 |
High Point Pharmaceuticals, Llc |
Adamantyl benzamide derivatives
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
DE102008062566A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Aminosäureester-Prodrugs und ihre Verwendung
|
DE102008062567A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Dipeptoid-Prodrugs und ihre Verwendung
|
DE102009006602A1
(de)
*
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
MX2011009414A
(es)
|
2009-03-11 |
2011-10-19 |
Kyorin Seiyaku Kk |
7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
|
JP2013503135A
(ja)
|
2009-08-26 |
2013-01-31 |
サノフイ |
新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
|
EP2482823A2
(en)
|
2009-10-02 |
2012-08-08 |
Sanofi |
Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
TW201121968A
(en)
*
|
2009-11-09 |
2011-07-01 |
Intermune Inc |
Novel inhibitors of hepatitis C virus replication
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
US20130012432A1
(en)
|
2010-02-26 |
2013-01-10 |
Novo Nordisk A/S |
Peptides for Treatment of Obesity
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
RU2559320C2
(ru)
|
2010-03-26 |
2015-08-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
WO2011161099A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Pharma Aktiengesellschaft |
Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
|
DE102010030688A1
(de)
|
2010-06-30 |
2012-01-05 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Dicyanopyridine und ihre Verwendung
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
US20120058983A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Pharma Aktiengesellschaft |
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
|
EP2683700B1
(de)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
AU2012234276A1
(en)
|
2011-03-28 |
2013-08-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
US9382305B2
(en)
|
2011-07-01 |
2016-07-05 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
JP2014529293A
(ja)
|
2011-07-08 |
2014-11-06 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
レラキシンを放出する融合タンパク質およびその使用
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
JP6352806B2
(ja)
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013144191A1
(de)
|
2012-03-29 |
2013-10-03 |
Bayer Intellectual Property Gmbh |
Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
|
US9416129B2
(en)
|
2012-10-17 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
|
WO2014062549A1
(en)
*
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
US9867869B2
(en)
|
2012-12-12 |
2018-01-16 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
JP6594856B2
(ja)
|
2013-04-18 |
2019-10-23 |
ノヴォ ノルディスク アー/エス |
医療用の安定な遷延性glp−1/グルカゴン受容体コアゴニスト
|
ES2708577T3
(es)
|
2013-09-04 |
2019-04-10 |
Univ Kyoto |
Composición medicinal que mejora la resistencia a la leptina
|
AU2014364735A1
(en)
|
2013-12-19 |
2016-07-07 |
Bayer Pharma Aktiengesellschaft |
Substituted piperidinyl-tetrahydroquinolines
|
JOP20200052A1
(ar)
|
2013-12-19 |
2017-06-16 |
Bayer Pharma AG |
بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
|
EP3083610A1
(de)
|
2013-12-19 |
2016-10-26 |
Bayer Pharma Aktiengesellschaft |
Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
|
EP3083594A1
(de)
|
2013-12-19 |
2016-10-26 |
Bayer Pharma Aktiengesellschaft |
Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
|
WO2015185640A1
(en)
|
2014-06-04 |
2015-12-10 |
Novo Nordisk A/S |
Glp-1/glucagon receptor co-agonists for medical use
|
EP3623371A1
(en)
|
2014-12-16 |
2020-03-18 |
Axovant Sciences GmbH |
Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
|
WO2016201096A1
(en)
|
2015-06-10 |
2016-12-15 |
Forum Pharmaceuticals, Inc. |
Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
|
US10428062B2
(en)
|
2015-08-12 |
2019-10-01 |
Axovant Sciences Gmbh |
Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
|
US20190008867A1
(en)
|
2015-11-13 |
2019-01-10 |
Ph Pharma Co., Ltd. |
4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
|
JP2020514365A
(ja)
|
2017-03-15 |
2020-05-21 |
ノヴォ ノルディスク アー/エス |
メラノコルチン4受容体に結合可能な二環式化合物
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
WO2020165031A1
(de)
|
2019-02-15 |
2020-08-20 |
Bayer Aktiengesellschaft |
Substituierte isochinolin-piperidinylmethanon-derivate
|